Moderna Inc.
Moderna Reports First Quarter 2026 Financial Results and Business Updates
Summary
Moderna, Inc. reported its first quarter 2026 financial results, showing total revenue of $389 million, a GAAP net loss of $(1.3) billion, and GAAP EPS of $(3.40). The company reiterated its plan for up to 10% revenue growth and GAAP operating expense reductions in 2026. Moderna also provided updates on its pipeline, including regulatory milestones for its infectious disease portfolio and the initiation of a Phase 3 clinical study for its oncology therapeutics.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement